Hemolysis Clinical Trial
Official title:
Elucidation of the Mechanism of IVIG-Associated Hemolysis
Patients at high risk of IVIG-associated hemolysis (defined as receipt of a 28-day cumulative dose of ≥ 2 g/kg, adjusted for ideal body weight, and non-O blood group) will be prospectively monitored using a standardized protocol for signs of hemolysis, and will be undergo additional testing for variables that have been hypothesized to increase the risk of hemolysis. The goal of the study is to define the incidence and dynamics of IVIG-mediated hemolysis and identify patient and product-related factors that may predict which patients are especially at risk.
All IVIG orders received by the blood transfusion service at participating sites will be
screened for patient eligibility. All non-O blood group patients receiving a cumulative
28-day dose of IVIG ≥ 2 g/kg will be approached for enrolment. Exclusion criteria include
the presence of an alternate cause of anemia, including blood loss, other drug-induced
hemolysis, anemia associated with chemotherapy for cancer, or hemolysis associated with an
underlying disease or participation in another ongoing study. Patients receiving repeated
courses of therapy will be eligible for re-enrollment a maximum of 6 times. There are
otherwise no exclusions on the basis of age, diagnosis, concurrent treatment, or specific
brand of product received. Enrolment will occur at multiple Canadian health care facilities.
Upon enrolment,case report forms documenting the participant's previous medical history,
IVIG treatments and adverse reactions, and concurrent medication use will be collected.
Laboratory testing for hemolysis will be performed at baseline, immediately following the
completed high-dose cycle (usually administered over 1-2 days), and then again at 5-10 days
post-infusion. IVIG associated. Hemolysis will be defined and graded as per the criteria of
the Canadian IVIG Pharmacovigilance Group. The pathophysiology of IVIG-associated hemolysis
will be characterized by tracking changes in serum complement levels, performing extended
cytokine profiling, and conducting mononuclear phagocyte activity assays using patient
monocytes. Secretor gene status, ABO zygosity and FcR polymorphisms will also be determined.
A predictive model incorporating both patient factors (eg., blood group, total dose
prescribed, presence of pre-infusion inflammation) and product factors (eg., specific lot
number) will then be developed.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03439605 -
Effect of in Vitro Haemolysis on Serum High Sensitivity Troponin T Measurements From Patients in Accident & Emergency
|
N/A | |
Completed |
NCT03434145 -
Changes of Ocular Structures After Hemodialysis in Patients With Chronic Kidney Diseases
|
N/A | |
Completed |
NCT04084301 -
Impact of Cardiopulmonary Bypass Flow on Renal Oxygenation, Blood Flow and Tubular Injury
|
N/A | |
Not yet recruiting |
NCT01201174 -
Hemolysis in Patients With Hereditary Spherocytosis (HS)
|
N/A | |
Completed |
NCT03582592 -
Fluid Distribution Timetable on Adherence to Fluid Restriction of Patients With End-Stage Renal Disease on Hemodialysis
|
N/A | |
Not yet recruiting |
NCT05754294 -
Electric Polarization of Red Blood Cells : A Cohort Study to Assess the Erythrocytes Membrane Integrity Through Charge Conservation, Following Cardiac Surgery.
|
||
Completed |
NCT02996786 -
Effects of Danggui Buxue Tang on Blood Biochemical Parameters in Male Recreational Runners
|
N/A | |
Not yet recruiting |
NCT05647200 -
Optimization of Prime Fluid Strategy to Preserve Microcirculatory Perfusion During Cardiac Surgery With Cardiopulmonary Bypass, Part II
|
N/A | |
Completed |
NCT05962268 -
The Effect Of Vıdeo-Based Fıstula Care Educatıon On Hemodıalysıs
|
N/A | |
Recruiting |
NCT06223802 -
Biodex Training in Hemodialysis Females With Osteopenia
|
N/A | |
Active, not recruiting |
NCT00792779 -
Protective Effect of Propofol Against Hemolysis in Patients Submitted to Gastroplasty
|
N/A | |
Not yet recruiting |
NCT06096428 -
Hemolysis During Pulsed-field and Radiofrequency Ablation
|
||
Recruiting |
NCT03330223 -
Effect of Haemodialysis on the Efficacy of Antiplatelet Agents
|
N/A | |
Completed |
NCT04203784 -
Meropenem and Piperacillin Plasma Concentrations During CRRT
|
||
Completed |
NCT06215339 -
Diet Therapy in Hemodialysis Patients
|
N/A | |
Recruiting |
NCT05539248 -
A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects With PNH
|
Phase 1/Phase 2 | |
Recruiting |
NCT03633435 -
Home Hemodialysis Assisted by a Nurse for Arterio-venous Fistula Cannulation
|
N/A | |
Withdrawn |
NCT02217683 -
Use of Inhaled Nitric Oxide to Prevent Pulmonary Hypertension Associated to Stored Blood Transfusion
|
Phase 2 | |
Completed |
NCT03199612 -
Sildenafil To Prevent Clot
|
Early Phase 1 | |
Completed |
NCT02711332 -
Investigating the Influence of Haemolysis on the Potassium Concentration After Capillary Blood Sampling
|
N/A |